What I Want You to Know About Lynch Syndrome in 2026

I carry the MLH1 mutation — one of five genes associated with Lynch syndrome, the most common hereditary colorectal cancer syndrome most people have never heard of. I lost my brother Jimmy to Lynch-related colon cancer at 36, before our family even knew this syndrome existed in our DNA. That loss, and my own diagnosis fifteen years ago, transformed me from patient to fierce advocate. And right now, in 2026, I have never had more reason to be hopeful — or more urgency to share what I know.

Here is what I most want you to know

Number one: See a certified genetic counselor.

The way someone talks about their diagnosis, their options, and their fear tells you everything. People who have worked with a certified genetic counselor speak with clarity and confidence. Those who haven't are often navigating in the dark, sometimes making decisions based on misinformation that could genuinely cost them — and the people who listen to them. You can find a certified genetic counselor at nsgc.org.

There are five genes associated with Lynch syndrome — MLH1, MSH2, MSH6, PMS2, and EPCAM — and the cancer risks, surveillance recommendations, and management strategies differ meaningfully between them. A certified genetic counselor helps you understand which gene you carry, what it means for your specific situation, and what questions to bring to your medical team. They also walk you through the ethical, financial, and life insurance implications of genetic testing that most people never think to ask about beforehand. And they can provide a letter to help you notify possibly affected family members. Genetic counseling and genetic testing are typically covered by health insurance.

If you have already received results without that conversation, go back and have it now. Think of genetic counseling not as a one-time appointment, but as a long-term partnership that will evolve alongside you. It is an important step you can take after a Lynch syndrome diagnosis.

A cancer prevention vaccine is no longer a distant dream

This is the advancement I have been watching with hope for years, and I still feel a particular kind of awe saying it out loud. The Tri-Ad5 vaccine, currently in a large-scale Phase IIb clinical trial at Dana-Farber Cancer Institute sponsored by the National Cancer Institute, is designed to train the immune system to recognize and destroy pre-cancerous cells before a tumor can take hold. A vaccine specifically designed to prevent the cancers we spend our lives dreading — this is not science fiction. This is happening.

NOUS-209, developed by Nouscom, is another prevention vaccine in trials targeting Lynch-related tumors. Data presented at SITC in November 2025 showed that annual revaccination effectively boosts durable T cell immunity — and notably, no advanced adenomas were detected in participants one-year post-treatment, offering the first clinical evidence of cancer interception. A study to enable registration is now being planned. We are watching this space closely, and we should be. If you are interested in enrolling in a clinical trial, start at clinicaltrials.gov.

Immunotherapy has changed the treatment landscape — but only if your doctor tests for it

Lynch syndrome tumors are characterized by microsatellite instability, which makes them highly responsive to immune checkpoint inhibitors. This class of immunotherapy has transformed outcomes for many patients with Lynch-associated cancer. But it only works if MSI and MMR status are tested — and that is not always happening automatically.

If you or someone you love receives a Lynch-related cancer diagnosis, ask your oncologist directly: Have you tested for MSI and MMR status? That question could change everything.

The aspirin conversation has been updated

For years, many of us have been advised by medical professionals to take high-dose aspirin as chemoprevention to lower Lynch-related cancer risk. The CaPP3 trial findings, presented at the Cancer Research UK Cancer Prevention Research Conference in June 2025, have shifted that guidance. Lower doses — between 75 and 100 mg daily — now appear to offer similar protection against colorectal cancer with a much safer side effect profile. If you are on a higher dose, bring it up with your doctor. And if you have never had the chemoprevention conversation, now is the time to start.

Universal tumor testing is now the standard. Make sure it happens.

All newly diagnosed colorectal and endometrial cancers should now be tested for MMR and MSI status — regardless of age or family history. This is how most Lynch syndrome diagnoses are made today, and NCCN guidelines support it across multiple cancer types. If you or a family member received either of those diagnoses without being tested, ask about it now. Do not wait.

Tell your family. Then mark March 22nd on your calendar.

Each first-degree relative — parent, sibling, child — has a 50% chance of carrying the same mutation. That conversation is hard. Tell them anyway. A letter from a genetic counselor can help open the door.

And if you are newly diagnosed and feeling alone in this, you are not. March 22nd is Lynch Syndrome Awareness Day. There is more reason for hope in 2026 than ever before—prevention vaccines, smarter chemoprevention, and immunotherapy that works. Researchers and advocates are working alongside us every single day. We are not standing at the edge of that cliff anymore. We are building a path, and every small choice is an investment in many hopeful tomorrows.

This piece reflects the author’s personal experience and perspective. For medical advice, please consult your health care provider.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.